drug prices

Politics By Lev Facher and Nicholas Florko

Sensing an advantage, Democrats dare Trump to talk drug prices during State of the Union

Pharmalot By Ed Silverman

Pharmalittle: Judge orders pause in suits against Purdue and Sacklers; Teva must face opioid trial

Pharmalot By Ed Silverman

Doctors Without Borders demands drug makers lower their prices for TB treatments

Pharmalot By Ed Silverman

A drug maker replaces an old treatment and boosts the price by 1,300%

Politics By Lev Facher

Former pharma hawk McCaskill: Drug pricing system is a ‘stinking stew of a mess’

Pharmalot By Ed Silverman

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Politics By Lev Facher

Kamala Harris becomes the latest Democratic candidate to zero in on drug prices

Pharmalot By Ed Silverman

Pharmalittle: Roche hits milestone with personalized cancer drug; data on a fountain of youth drug

Pharmalot By Ed Silverman

AIDS groups criticize Express Scripts for excluding several HIV medicines

Pharmalot By Ed Silverman

Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

Pharmalot By Ed Silverman

Generic drug price-fixing suit is akin to earlier case, but ‘on steroids,’ Conn. prosecutor says

Pharmalot By Ed Silverman

Seeking to contain drug costs, CMS may have ‘killed’ a PBM billing practice

First Opinion By John Arnold

John Arnold: Trump administration’s good effort on drug rebates is bad policy

Pharmalot By Ed Silverman

Pharmalittle: A Pfizer and Lilly painkiller misses study goals; LA County joins statewide effort to lower drug prices

Pharmalot By Ed Silverman

Lilly discloses pricing data on insulin in response to political pressure

Pharmalot By Ed Silverman

Vertex CEO says he will bring ‘new ideas’ to break a stalemate in the U.K. over a cystic fibrosis drug

Pharmalot By Ed Silverman

The ‘Netflix’ model for hepatitis C drugs is saving Australia a lot of money

Pharmalot By Ed Silverman

Lawmakers ask FDA to explain steps to contain contaminants in blood pressure drugs

Pharmalot By Ed Silverman

U.K. lawmaker challenges the government to issue a compulsory license for Vertex drug

Pharmalot By Ed Silverman

Vertex faces more pressure over pricing, but one analyst does not expect any movement

Pharmalot By Ed Silverman

Pharmalittle: AstraZeneca chief medical officer is leaving; a venture capital firm bids farewell to J.P. Morgan

Pharma By Ed Silverman and Matthew Herper

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

Pharmalot By Ed Silverman

Canada ends a probe into three big drug makers accused of thwarting generic competition

Pharmalot By Ed Silverman

Trump administration report would preclude reclaiming patents as a way to lower drug prices

Pharmalot By Ed Silverman

As pharma seeks more orphan drug designations, FDA fails to assess important needed info